Neuroendocrine Cancer Clinical Trials in Los Angeles, California
2 recruitingLos Angeles, California
Showing 1–2 of 2 trials
Recruiting
Phase 1
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 1
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Locally Advanced Merkel Cell CarcinomaSmall Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine Cancer+8 more
SystImmune Inc.120 enrolled20 locationsNCT07080242